No­var­tis to de­cide on spin­ning off $25B gener­ics arm San­doz by year's end

Ru­mors of No­var­tis spin­ning off its gener­ic and biosim­i­lars arm San­doz have been cir­cu­lat­ing since at least 2019.

Now, San­doz says a de­ci­sion from No­var­tis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER